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Background: Hypoxia-inducible factor 1 (HIF-1) is a transcrip-
tion factor that plays an important role in tumor growth by regulat-
ing the energy metabolism and angiogenesis. We herein investigated
the mRNA expression level of HIF-1 in non-small cell lung cancer
(NSCLC) tissues to clarify the impact on the clinical aspects of
NSCLC patients.
Experimental Design: HIF-1 mRNA derived from either a tumor
or an adjacent lung tissue was quantified using quantitative reverse
transcription polymerase chain reaction in 66 patients with NSCLC.
The relationship between the mRNA expression level of HIF-1 and
clinicopathological factors was investigated.
Results: The expression level of HIF-1 mRNA, which correlated
with its protein level, was significantly higher in tumor tissue than in
the corresponding nontumor-bearing lung tissue (4.22  104 
4.99  104 versus 1.24  104  1.15  104; p  0.001). The level
of HIF-1 mRNA showed a significantly positive correlation with
the mRNA levels of vascular endothelial growth factor and type II
hexokinase in tumors (p  0.0001 for each). In node-negative
patients, high expression levels of HIF-1 mRNA in tumors were
associated with a poor prognosis (p  0.0401), but not in the
node-positive cases.
Conclusion: The expression of HIF-1 mRNA is associated with
disease progression in NSCLC tissues, and is expected as a biomar-
ker or therapeutic target.
Key Words: Hypoxia inducible factor, Vascular endothelial growth
factor, Type II hexokinase, Non small cell lung carcinoma.
(J Thorac Oncol. 2009;4: 284–290)
Neovascularization and cellular adaptation to hypoxiahave been recognized to be essential conditions for
cancer progression. However, the mechanisms of such cellu-
lar events have not yet been fully elucidated.1–3 A key factor
in this adaptation is hypoxia-inducible factor 1 (HIF-1).
HIF-1 is a transcription factor that mediates the adaptive
responses to changes in tissue O2 levels.4,5 It is a het-
erodimeric, redox-sensitive protein composed of the basic
helix-loop-helix, Per-Arnt-Sim subunits, HIF-1, and consti-
tutively expressed HIF-1, the latter of which is also known
as aryl hydrocarbon receptor nuclear translocator.6–9 When
normal cells have normal concentrations of oxygen, HIF-1
protein is continuously degraded via the ubiquitin-proteo-
some pathway, however, under lower concentrations of oxy-
gen, the protein is stabilized by blocking the ubiquitina-
tion,8,10 and, as a result, the protein’s intracellular levels
increase.
More than 60 various HIF-1 target genes have recently
been identified; namely they are involved in angiogenesis,
apoptosis, vasomotor control, and erythropoiesis, as well as
the energy metabolism.11 Because the activation of these
genes by HIF-1 enables the cells to adapt to the changed
environment, the focus of HIF-1 may be to increase the
survival of tumor cells under hypoxic conditions.12,13 Re-
cently, anticancer therapy to inhibit HIF-1 has been reported
in an in vitro experimental study. Matthews et al.14 reported
the administration of nitric oxide- donating drugs to decrease
the hypoxia-induced resistance to anticancer drugs in cancer
cell lines. Clinically, in an investigation which suggested the
efficacy of anticancer therapy to inhibit HIF-1, Yasuda et al.15
reported a randomized phase II trail; comparing nitroglycerin
plus platinum-based chemotherapy with chemotherapy alone
in previously untreated stage III/IV non-small cell lung car-
cinoma (NSCLC). This combinational treatment may there-
fore enhance the response rate to its anticancer drugs, elon-
gate the time to progression, and improve the overall survival.
Recently, an overexpression of HIF-1 protein has
been demonstrated in various human clinical cancers includ-
ing NSCLC by immunohistochemistry3, and the relevance of
an overexpression of HIF-1 protein on the prognosis has
also been investigated. In NSCLC, however, it remains con-
troversial regarding whether the overexpression of HIF-1
protein is associated with a progression of this disease.16,17
An overexpression of mRNA of HIF-1 has been reported in
both clinical and experimental cancers.18–20 Matsuyama et
al.21 reported the HIF-1 mRNA scores to significantly cor-
relate with the scores for HIF-1 protein expression in
clinical esophageal cancer. Such an abnormal up-regulation
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of HIF-1 protein in cancers may therefore contribute to
other mechanisms than the response of normal cells to
hypoxia.
The objective of our study was to thus examine the
impact of HIF-1 mRNA expression on the disease progres-
sion, and clarify the relationship between HIF-1 and the
gene expression of the downstream effectors of the hypoxia
response element (HRE), such as vascular endothelial growth
factor (VEGF) and type II hexokinase (HKII), using quanti-
tative reverse transcription polymerase chain reaction (PCR),
and also to investigate the clinical significance in the expres-
sion of HIF-1 mRNA on the progression of NSCLC.
PATIENTS AND METHODS
Patients
The subjects of this study consisted of 66 patients with
NSCLC who underwent a surgical resection at the Depart-
ment of Surgery II, Kyushu University Hospital, Fukuoka,
Japan, between 1996 and 2000. No patients had received any
prior anticancer treatment. They included 50 adenocarcino-
mas (Ad) and 16 squamous cell carcinomas (Sq), and 37
stage I, 7 stage II and 22 stage III cases. The tumor types and
stages were histologically classified according to the World
Health Organization classification method22 and the Tumor,
Node, Metastasis System,23 respectively. Information about
the lung cancer patients was obtained from hospital records.
Immunohistochemistry
Surgical specimens were immediately transferred from
the operation rooms to the laboratory, fixed in 3% formalde-
hyde for 7 days, and then were embedded in paraffin. The
sections from the paraffin-embedded blocks were transferred
to poly-L-lysine-coated glass slides and air-dried overnight at
37°C. They were dewaxed in xylen (three changes), rehy-
drated in a graded series of decreasing ethanol concentra-
tions, and then rinsed in Dulbecco phosphate-buffered saline.
For the detection of HIF-1, tissue sections were immersed in
10 mmol/liter citrate buffer (pH 6.0) and then were subjected
to microwave irradiation for 45 minutes 1. After antigen
retrieval, the sections were allowed to cool for 20 minutes
and then were immersed for 5 minutes in water containing
3% hydrogen peroxide for the blockage of the endogenous
peroxidase activity. Monoclonal anti-HIF-1 antibody (clone
monoclonal antibody H167, NB 100-123; Novus Biologic,
Littleton, CO) at a dilution of 1:1000 was incubated with the
tissue sections for 1 hour at 20°C in a moisture chamber.
Thereafter, the catalyzed signal amplification system
(DAKO, Carpinteria, CA) was used according to the manu-
facturer’s instructions.3 The reaction products were visual-
ized by exposing the sections to 3,3-diaminobenzidine for
HIF-1. The nuclei were lightly counterstained for about 5
minutes with Meyer’s hematoxylin. The sections were then
mounted. Tissue samples incubated with nonimmune serum
served as negative controls. Esophageal cancer tissue sections
with strong nuclear HIF-1 expression were used as positive
controls. The frequency of the nuclear staining was evaluated
without any knowledge of either the clinical or pathologic
status data. Five fields (400) were analyzed to determine
the frequency of the HIF-1 stained nuclei. At least 500
tumor cells in the five fields were counted, HIF-1 staining
was regarded as positivity if the tumor cells of more than 1%
within tumor tissue showed completely darkly stained nuclei.
Any cytoplasmic staining which was occasionally observed,
was ignored because active HIF-1 is only located in the
nucleus.24,25 The staining was independently graded by two
of the authors.
Total RNA Extraction and First-Strand cDNA
Synthesis
Total RNA was extracted from surgically resected pri-
mary tumors. Adjacent normal lung tissue specimens were
immediately snap-frozen and then were stored in liquid ni-
trogen, using ISOGEN (Nippon Gene, Inc., Tokyo, Japan)
according to the manufacturer’s protocol. The quantity and
quality of the extracted RNA were determined spectrophoto-
metrically by absorbance at 260 and 280 nm. cDNA was
synthesized with 2.0 g of total RNA using a First-Strand
cDNA synthesis Kit (Amersham Pharmacia Biotech, Piscat-
away, NJ).26
Real-Time Quantitative Reverse
Transcription-Polymerase Chain Reaction
Real-time reverse transcription-PCR is a sensitive,
quantitative, and highly reliable method for quantifying
RNA. The theoretical basis of this method has been previ-
ously described.27,28 The target gene’s mRNA levels were
quantified using the ABI Prism 7700 Sequence Detection
System (Perkin-Elmer Corp., Foster City, CA). Primers and
Taqman probes (Custom Oligonucleotide Factory, Foster
City, CA) were designed to span the exon-intron junctions to
prevent an amplification of genomic DNA and also to pro-
duce amplicons of fewer than 200 bp, thereby enhancing the
efficiency of PCR amplification. The probes were labeled at
the 5-end with the reporter dye molecule 6-carboxy-flores-
cein (emission max  582 nm) and at the 3-end with the
quencher dye molecule 6-carboxytetramethyl-rhodamine
(emission max  582 nm). Upon amplification, the probes
which annealed to the template are then cleaved by the 5
nuclease activity of the Taq polymerase reaction. This pro-
cess separates the fluorescent label from the quencher and
thus allows the release of one unit of fluorescence for each
unit of amplification. By determining the amount of fluores-
cence with each cycle, it is thus possible to determine the
number of cycles necessary to reach a chain amount of
fluorescence in a test sample in comparison with the known
standard amounts of a template provided as a standard curve.
DNA strands were generated by PCR amplification of the
gene products, purification, and quantification by spectropho-
tometry (absorbance at 260 nm). The number of copies was
then calculated using the weight of the molecular gene.
Real-time PCR of cDNA specimens and DNA strands was
conducted in a total volume of 25 l with 1Taqman Master
Mix (Perkin-Elmer), primers at 15 M and probes at 10 M.
The HIF-1 primer sequences were as follows: forward
primer, 5-AGTGTACCCTAACTAGCCGAGGAA; reverse
primer, 5-TACCCACACTGAGGTTGGTTACTG; and Taq-
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man probe, TGTGGCCTGTGCAGTGCAATACCTT. In ad-
dition, the VEGF and HK II primer sequences were as
follows: forward primer, 5-CCCACTGAGGAGTCCAA-
CATC; reverse primer, 5-ACATTTGTTGTGCTGTAGGAA-
GCT; Taqman probe, TGCAGATTATGCGGATCAAACCTC-
ACC, and forward primer, 5-GGCTGTGGATGAGCTTT-
CACT; reverse primer, 5-TCCACGCTTGGTGAAATCG;
Taqman probe, TTCTCGAACCTCTGCTTGCCGG. The ther-
mal cycler parameters included a 2-minute incubation at 50°C,
10 minutes at 95°C, and 40 cycles of denaturation at 95°C for
15 seconds and annealing/extension at 60°C at 10 minutes.
Each sample was analyzed in duplicate, and a calibration
curve was constructed using a 10-fold serial dilution of a total
extracted from an arbitrarily resected tumor sample was run
in parallel with each analysis. The coefficient of correlation
was r  0.98, and the slope was constant in each experiment.
As an internal control, the same samples were tested for
-actin mRNA (Perkin-Elmer) in the same manner.
Statistical Analysis
For the statistical analyses, the StatView-J 5.0 software
package (SAS Institute Inc.) was used. The relationship
between the HIF-1 mRNA expression and VEGF mRNA,
HK II mRNA, pack-year index, or tumor size was examined
using either the Mann-Whitney U test or a regression analy-
sis. The relationship between the HIF-1 protein and the
HIF-1 mRNA, the HRE-downstream genes mRNA such as
VEGF and HK II were examined using the Mann-Whitney U
test. In addition, the relationship between the HIF-1 mRNA
expression status and the clinicopathological factors accord-
ing to the gender, histology, pathologic stage, lymph node
status, lymphatic permeation and vascular permeation were
examined using the 2 test.
Survival curves were figured using the Kaplan-Meier
method,29 and differences between the curves were analyzed
with the log-rank test.30 For all tests, a value of p  0.05 was
considered to be significant.
RESULTS
Expression of HIF-1 mRNA in NSCLC Tissues
The HIF-1 mRNA expression of tumor tissues and
nontumor- bearing lung tissues from 66 patients was quanti-
fied. The HIF-1 mRNA were significantly higher in the
tumor tissue specimens than in the normal tissue specimens.
The mean copy numbers of mRNA was 4.22 104 4.99
104 copies/0.08 g total mRNA in tumor tissues and 1.24 
104  1.15  104 copies/0.08 g total mRNA in normal
tissues (p  0.001). We confirmed that the level of -actin
expression, which served as an internal control, was almost
the same in the tumor and normal lung tissue specimens (data
not shown).
Detection of HIF-1 Protein in NSCLC Tissues
We confirmed the HIF-1 protein expression by an
immunohistochemistry analysis in 59 cases, and two repre-
sentative cases are shown in Figure 1. A diffuse and strong
nuclear expression was recognized in the adenocarcinoma
case (Figure 1A), whereas the HIF-1 expression was either
very weak or completely absent in the other adenocarcinoma
case (Figure 1B). When we statistically evaluated the rela-
tionship between the HIF-1 protein and HIF-1 mRNA,
VEGF mRNA, HK II mRNA, a positive correlation was
observed between HIF-1 protein and HIF-1 mRNA (p 
0.0296), HK II mRNA (p  0.0303), and positive tendency
was observed between HIF-1 protein and VEGF mRNA
(p  0.0956). However, the HIF-1 protein expression did
not correlate with the expression of Prl-3 mRNA, which is
known to be a phosphatase that affects the metastatic poten-
tial in colorectal cancer and NSCLC31,32 (Table 1).
Relationship Between the Expression of HIF-1
mRNA and that of the HRE-Downstream Gene
We examined the relationship between the mRNA
expression level of HIF-1 and the mRNA expression of
the genes downstream of HRE. The copy number of
HIF-1 mRNA positively correlated with that of VEGF
mRNA (  0.78, p  0.0001) (Figure 2A), and that of HK
II mRNA levels (  0.61, p  0.0001) (Figure 2B).
However, the HIF-1 mRNA expression was not corre-
lated with the expression of Prl-3 mRNA (  0.193, p 
0.2517) (Figure 2C).
FIGURE 1. Immunohistochemical analysis of hypoxia-induc-
ible factor 1 (HIF-1) protein. Each panel shows the immu-
nohistochemical staining reaction findings using an anti-
HIF-1 protein antibody for a representative case. A, A
diffuse and strong nuclear expression was recognized in this
adenocarcinoma case. B, The HIF-1 expression was either
weak or absent in another adenocarcinoma case.
TABLE 1. The Relationship Between the Expression Status
of HIF-1 Protein and Expression of mRNA of HIF-1 and
HRE-Downstream Genes
Expression of HIF-1
Protein
p
Positive Negative
(n  35) (n  24)
HIF-1 mRNA copy numbera 5.2  104 2.8  104 0.0296
VEGF mRNA copy numbera 5.5  104 3.2  104 0.0956
HK II mRNA copy numbera 3.9  104 1.8  104 0.0303
PRL-3 mRNA copy numbera 7.1  104 6.2  104 0.7362
a Values given as the mean.
HIF-1, Hypoxia-inducible factor 1; VEGF, Vascular endothelial growth factor;
HKII, Type II hexakinase, PRL-3, Phosphatase of regenerating liver-3.
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Relationships Between the Expression Status of
HIF-1 mRNA and Clinicopathological Factors
The copy number of HIF-1 mRNA did not show a
positive correlation with either the pack-year index or with
the tumor size (data not shown). No significant association
between the expression status of HIF-1 mRNA and the
clinico-pathologic factors such as gender, histology, lymph
node status, lymphatic permeation, and vascular permeation
was observed. However, there tended to be a positive corre-
lation between the expression status of HIF-1 mRNA and
the pathologic stage (Table 2).
Survival Analysis
To analyze the impact of the expression of HIF-1
mRNA on survival, the patients were divided into two sub-
groups according to the high or low expression level of the
HIF-1 mRNA copy numbers. The patients with more than
the median number of HIF-1 mRNA copies were defined as
the high-expression group. A survival analysis showed no
significant difference between the high expression and low
expression subgroups (Figure 3A). Since the presence of
lymph node metastasis is a strong prognostic factor, as shown
in Figure 3B, an analysis was thus performed for each
subpopulation. The high-expression group exhibited a signif-
icantly lower survival rate in comparison with the low-
expression group when the analysis focused on patients with
no lymph node metastasis (p  0.0417) (Figure 3C). In the
lymph node positive patients, there was no significant differ-
ence in the survival between the high and low expression
subgroups (Figure 3D).
TABLE 2. The Relationship Between the Status of HIF-1
mRNA Expression and Clinicopathological Factors
Clinicopathologic Factors
Patients
Number
Status of HIF-1
mRNA Expression
p
High group Low group
(n  33) (n  33)
Gender
Male 40 20 (49%) 20 0.9999
Female 26 13 (50%) 13
Histologic type
Adenocarcinoma 50 24 (48%) 26 0.5657
Squamous cell carcinoma 16 9 (56%) 7
Pathological stage
I 37 15 (41%) 22 0.0790
II 7 6 (86%) 1
III 22 12 (55%) 10
Lymph node status
Positive 21 12 (57%) 9 0.4279
Negative 45 21 (47%) 24
Lymphatic permeation
Positive 20 12 (60%) 8 0.2840
Negative 46 21 (46%) 25
Vascular permeation
Positive 21 11 (52%) 10 0.7916
Negative 45 22 (49%) 23
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FIGURE 2. The relationship between the expression level of
hypoxia-inducible factor 1 (HIF-1) mRNA and the mRNA
expression of the genes located downstream of hypoxia re-
sponse element (HRE). A, The relationship between the ex-
pression levels of HIF-1 mRNA and vascular endothelial
growth factor (VEGF) mRNA. A positive correlation was statis-
tically significant (  0.781, p  0.0001). B, The relationship
between the expression level of HIF-1 mRNA and hexokinase
II mRNA. A positive correlation was statistically significant ( 
0.611, p  0.0001). C, The relationship between the expres-
sion levels of HIF-1 mRNA and PRL3 mRNA. The correlation
was not significant (  0.193, p  0.2517).
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For an analysis of the HRE-downstream gene in the
node-negative subgroup, both VEGF and HK II were dem-
onstrated to be more highly expressed in the higher HIF-1
expression cases (p  0.0001 and p  0.0008, respectively)
than in the lower HIF-1 expression cases. In the node-
positive subgroup, no significant difference was observed in
the HK II expression between the higher and lower HIF-1
expression cases (Table 3).
DISCUSSION
The purpose of this study was to investigate the expres-
sion levels of HIF-1 mRNA in NSCLC and the impact of
those levels on the progression of that disease. Thus far,
several authors have reported high levels of HIF-1 protein
level to be predictive of a poor prognosis in a broad range of
carcinomas, such as early cervical carcinoma,33 oropharyn-
geal carcinoma,34 oligodendrogliomas,35 and NSCLC.16 In
contrast, other studies have revealed no correlation between
the HIF-1 protein level and the survival of patients.17,36,37 In
our study, a significant correlation was not recognized be-
tween the HIF-1 protein level and its prognosis (data not
shown). These conflicting results may be partly explained by
quantitative analyses of the immunohistochemically evalu-
ated protein levels. Up to now, HIF-1 protein has been
considered to be regulated by the degradation of the protein,
not by the expression of mRNA. However, several cancers
such as bladder cancer,18 renal cancer,19 esophageal cancer,21
and experimental rat cancer20 have recently been demon-
strated to overexpress HIF-1 mRNA. More recently, Lau et
al.38 reported a three-gene mRNA expression-based classifier,
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FIGURE 3. A survival analysis ac-
cording to the status of the hypoxia-
inducible factor 1 (HIF-1) mRNA
expression and of lymph node me-
tastasis. A, A survival curve for all the
patients showed no statistically sig-
nificant difference between the high-
expression group and the low-ex-
pression group (p  0.2184). B, A
survival curve for all the patients
showed a significant difference be-
tween the lymph node positive and
negative cases (p  0.0007). C, A
survival curve for the lymph node-
negative patients showed a signifi-
cant difference between the high
and low-expression groups (p 
0.0417). D, A survival curve for the
lymph node- positive patients
showed no significant difference be-
tween the high and low-expression
groups (p  0.3948).
TABLE 3. The Relationship Between the Status of HIF-1 mRNA Expression and Expression of mRNA of
HRE-Downstream Genes in Node-Negative and -Positive Patients
Subgroups Status of HIF-1 mRNA Expression VEGF mRNA Copy Numbera HK II mRNA Copy Numbera
Total (n  66) High group (n  33) 7.0  104 4.3  104
Low group (n  33) 2.0  104 1.5  104
(p  0.0001) (p  0.0004)
Node-positive (n  21) High group (n  12) 8.3  104 5.1  104
Low group (n  9) 2.0  104 2.2  104
(p  0.0018) (p  0.1416)
Node-negative (n  45) High group (n  21) 6.3  104 4.0  104
Low group (n  24) 2.0  104 1.3  104
(p  0.0001) (p  0.0008)
a Values given as the mean.
HIF-1, Hypoxia-inducible factor 1; VEGF, vascular endothelial growth factor; HRE, hypoxia response element.
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including HIF 1, that is independent of and improves on
stage to stratify early-stage NSCLC patients with signifi-
cantly different prognoses, as a result of having evaluated the
significance of 158 genes in 147 early-stage completely
resected NSCLC patients using quantitative reverse transcrip-
tion-PCR. In this study, the mRNA of HIF-1 was therefore
analyzed by a comparison of both the protein expression and
clinicopathological factors. We herein demonstrated that the
mRNA level was significantly higher in tumor tissue speci-
mens than in nontumor-bearing lung tissues, and that it
correlated to the protein expression level. Therefore, a sub-
sequent clinicopathologic analysis was performed using the
quantitative data of the mRNA copy numbers. When analyz-
ing the expression status of HIF-1 mRNA and clinicopath-
ologic factors, a positive correlation tended to be observed
between the high expression of HIF-1 mRNA and patho-
logic stage. Considering the influence of this phenomenon on
the prognosis, the expression level of HIF-1 mRNA was
thus not considered to be associated with the postoperative
prognosis in all patients. However, in node-negative patients,
high levels of HIF-1 mRNA were indicated to be a factor
indicating a poor prognosis.
HIF-1 is considered to support tumor growth by the
induction of angiogenesis via the expression of the VEGF and
also by high and anaerobic metabolic mechanisms.39 The
present study is the first to demonstrate a strong association
between the levels of HIF-1 mRNA and VEGF mRNA/
HK-II mRNA in human neoplasms, which are well known to
be downstream effectors of HRE.40–42
Despite the positive correlations between mRNA and
protein levels of HIF-1, only the mRNA level had an impact
on the survival of patients. As a result, conventional immu-
nohistochemical staining methods are therefore most likely
insufficient for performing a precise analysis of HIF-1
derived from clinical tumor specimen, since the HIF-1
protein may degenerate immediately during the handling of
the resected materials. As an another explanation for the
issue, the mRNA levels may reflect the exposure to growth
factors of the tumor cells as well as HRE-downstream genes
would be activated.
These results thus suggest that HIF-1 plays a central
role in the progression of NSCLC. In this study, the impact of
HIF-1 expression on survival was only demonstrated in the
node-negative patients. The expression status of VEGF and
HK II was consistently higher in the HIF-1-high expression
cases regardless of the status of node metastasis (Table 3).
Recently, the detection of small-sized lung cancers has be-
come more frequent due to advancements in various diagnos-
tic tools and modalities,43 although some phenotypes of such
cancers do not represent local disease. HIF-1 is thus con-
sidered to potentially be a significant biomarker for occult
metastasis in node-negative NSCLC.
In general, HIF-1 accumulation is regulated by a
post-translational modification, namely an oxygen-dependent
pathway, through the rapid ubiquitination and proteasomal
degradation by HIF-1 prolyl hydroxylases44,45 under non-
hypoxic conditions,46–48 while this process is inhibited under
hypoxic conditions.49 However, a hypoxia-independent acti-
vation of HIF-1 through growth factors, hormones, nitiric
oxide, or cytokines has also recently been recognized. The
growth factors clarified thus far, including insulin,50 insulin-
like growth factor,50,51 epidermal growth factor,52 and inter-
leukin-1,53 are known to enhance the expression of HIF-1
via such signal transduction as the Phosphatidylinositol 3-
kinase -Akt- FKBP-rapamycin -associated protein pathway or
the mitogen-activated protein kinase pathway.11 Cytokines
such as interleukin-1 and tumor necrosis factor  have also
been reported to have an influence on the HIF-1 stability
regulation.54,55 Regarding the mechanism of the regulation of
these cytokines, several authors have reported the formation
of reactive oxygen species and activation of nuclear factor B
and/or Phosphatidylinositol 3-kinase to be involved incon-
veying a tumor necrosis factor- signal which thus results in
HIF-1 up-regulation.56–58 The above hypoxia-independent
pathway for HIF-1 up-regulation may thus be involved in
clinical cancers. In this study, a similar mechanism to such an
oxygen-independent pathway was also suggested to contrib-
ute to the high HIF-1 expression in NSCLC, since no
positive correlation between the HIF-1 mRNA level and the
tumor size has yet been recognized, and a significant over-
expression of HIF-1 mRNA, which is not involved in the
oxygen-dependent pathway was noted.
In summary, this study confirms a high level of HIF-1
mRNA in NSCLC, and first demonstrates that its high ex-
pression level indicates an unfavorable prognosis in node-
negative NSCLC. These results therefore help us to under-
stand the biologic aspects of NSCLC, while also suggesting
new concepts of biomarker or of developing molecular-
targeted treatments for NSCLC.
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